Heart 1999;81:114-120 ( February )

Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction

A M Richards,^a M G Nicholls,^d T G Yandle,^b H Ikram,^a E A Espiner,^b J G Turner,^c R C Buttimore,^d J G Lainchbury,^a J M Elliott,^a C Frampton,^d I G Crozier,^a D W Smyth^a, (The Christchurch Cardioendocrine Research Group)

^a Department of Cardiology, Christchurch Hospital, PO Box 4345, Christchurch, New Zealand, ^b Department of Endocrinology, Christchurch Hospital, ^c Department of Nuclear Medicine, Christchurch Hospital, ^d Department of Medicine, Christchurch School of Medicine, Riccarton Avenue, Christchurch, New Zealand

Correspondence to: Professor Richards. email: bgriffin{at}chmeds.ac.nz

Accepted for publication 14 September 1998

ObjectiveTo determine the relations of plasma levels of brain natriuretic peptide (BNP), atrial natriuretic factor (ANF), N-terminal ANF (N-ANF), cyclic guanosine monophosphate (cGMP; the cardiac peptide second messenger), and plasma catecholamines to left ventricular function and to prognosis in patients admitted with acute myocardial infarction.
DesignPlasma hormones and ventricular function (radionuclide ventriculography) were measured 1-4 days after myocardial infarction in 220 patients admitted to a single coronary care unit. Radionuclide scanning was repeated 3-5 months after infarction. Clinical events were recorded over a mean period of 14 months.
ResultsBoth early and late left ventricular ejection fraction (LVEF) were most closely related to plasma BNP (r = 0.60, n = 220, p < 0.001; and r = 0.53, n = 192, p < 0.001, respectively), followed by ANF, N-ANF, cGMP, and the plasma catecholamines. Early plasma BNP concentrations less than twofold the upper limit of normal (20 pmol/l) had 100% negative predictive value for LVEF < 40% at 3-5 months after infarction. In multivariate analysis incorporating all the neurohormonal factors, only BNP remained independently predictive of LVEF < 40% (p < 0.005). Survival analysis by median levels of candidate predictors identified BNP as the most powerful discriminator for death (p < 0.0001). No early deaths (within 4 months) occurred in patients with plasma BNP concentrations below the group median (27 pmol/l), and over follow up only three of 26 deaths occurred in this subgroup. Of all episodes of left ventricular failure, 85% occurred in patients with plasma BNP above the median (p < 0.001). In multivariate analyses, BNP alone gave additional predictive information beyond sex, age, clinical history, LVEF, and plasma noradrenaline for both subsequent onset of LVF and death.
ConclusionsPlasma BNP measured within 1-4 days of acute myocardial infarction is a powerful independent predictor of left ventricular function, heart failure, or death over the subsequent 14 months, and superior to ANF, N-ANF, cGMP, and plasma catecholamines.

Keywords: cardiac natriuretic peptides; noradrenaline; myocardial infarction; heart failure

---

© 1999 by Heart
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Palmer, B. R., Pilbrow, A. P., Frampton, C. M., Yandle, T. G., Skelton, L., Nicholls, M. G., Richards, A. M. (2008). Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J 29: 2489-2496 [Abstract] [Full Text]  
• Hillock, R J, Frampton, C M, Yandle, T G, Troughton, R W, Lainchbury, J G, Richards, A M (2008). B-type natriuretic peptide infusions in acute myocardial infarction. Heart 94: 617-622 [Abstract] [Full Text]  
• Mocatta, T. J., Pilbrow, A. P., Cameron, V. A., Senthilmohan, R., Frampton, C. M., Richards, A. M., Winterbourn, C. C. (2007). Plasma Concentrations of Myeloperoxidase Predict Mortality After Myocardial Infarction. J Am Coll Cardiol 49: 1993-2000 [Abstract] [Full Text]  
• NACB WRITING GROUP MEMBERS, , Morrow, D. A., Cannon, C. P., Jesse, R. L., Newby, L. K., Ravkilde, J., Storrow, A. B., Wu, A. H.B., Christenson, R. H. (2007). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. Circulation 115: e356-e375 [Full Text]  
• NACB WRITING GROUP MEMBERS, , Morrow, D. A., Cannon, C. P., Jesse, R. L., Newby, L. K., Ravkilde, J., Storrow, A. B., Wu, A. H.B., Christenson, R. H., NACB COMMITTEE MEMBERS, , Christenson, R. H., Apple, F. S., Cannon, C. P., Francis, G., Jesse, R. L., Morrow, D. A., Newby, L. K., Ravkilde, J., Storrow, A. B., Tang, W., Wu, A. H.B. (2007). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. Clin. Chem. 53: 552-574 [Full Text]  
• Latour-Perez, J., Coves-Orts, F. J., Abad-Terrado, C., Abraira, V., Zamora, J. (2006). Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: A systematic review. Eur J Heart Fail 8: 390-399 [Abstract] [Full Text]  
• Qian, J.-Y., Leung, A., Harding, P., LaPointe, M. C. (2006). PGE2 stimulates human brain natriuretic peptide expression via EP4 and p42/44 MAPK. Am. J. Physiol. Heart Circ. Physiol. 290: H1740-H1746 [Abstract] [Full Text]  
• Ha, J.-W., Cho, J.-R., Kim, J.-M., Ahn, J.-A., Choi, E.-Y., Kang, S.-M., Rim, S.-J., Chung, N. (2005). Tissue Doppler-Derived Indices Predict Exercise Capacity in Patients With Apical Hypertrophic Cardiomyopathy. Chest 128: 3428-3433 [Abstract] [Full Text]  
• Ferrier, K., Campbell, A., Yee, B., Richards, M., O'Meeghan, T., Weatherall, M., Neill, A. (2005). Sleep-Disordered Breathing Occurs Frequently in Stable Outpatients With Congestive Heart Failure. Chest 128: 2116-2122 [Abstract] [Full Text]  
• Cleland, J G F, Torabi, A, Khan, N K (2005). Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction. Heart 91: ii7-ii13 [Abstract] [Full Text]  
• Jarai, R., Iordanova, N., Jarai, R., Raffetseder, A., Woloszczuk, W., Gyongyosi, M., Geyer, G., Wojta, J., Huber, K. (2005). Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide. Eur Heart J 26: 250-256 [Abstract] [Full Text]  
• Rodeheffer, R. J. (2004). Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004?. J Am Coll Cardiol 44: 740-749 [Abstract] [Full Text]  
• Cochet, A., Zeller, M., Cottin, Y., Robert-Valla, C., Lalande, A., L'Huilllier, I., Comte, A., Walker, P. M., Desgres, J., Wolf, J.-E., Brunotte, F. (2004). The extent of myocardial damage assessed by contrast-enhanced MRI is a major determinant of N-BNP concentration after myocardial infarction. Eur J Heart Fail 6: 555-560 [Abstract] [Full Text]  
• Mega, J. L., Morrow, D. A., de Lemos, J. A., Sabatine, M. S., Murphy, S. A., Rifai, N., Gibson, C. M., Antman, E. M., Braunwald, E. (2004). B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: An ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 44: 335-339 [Abstract] [Full Text]  
• Cleland, J. G.F., Goode, K. (2004). Natriuretic peptides for heart failure. Fashionable? Useful? Necessary?. Eur J Heart Fail 6: 253-255 [Full Text]  
• Hartmann, F., Packer, M., Coats, A. J.S., Fowler, M. B., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Trawinski, J., Amann-Zalan, I., Hoersch, S., Katus, H. A. (2004). NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail 6: 343-350 [Abstract] [Full Text]  
• de Denus, S., Pharand, C., Williamson, D. R. (2004). Brain Natriuretic Peptide in the Management of Heart Failure: The Versatile Neurohormone. Chest 125: 652-668 [Abstract] [Full Text]  
• Berendes, E., Schmidt, C., Van Aken, H., Hartlage, M. G., Rothenburger, M., Wirtz, S., Scheld, H. H., Brodner, G., Walter, M. (2004). A-Type and B-Type Natriuretic Peptides in Cardiac Surgical Procedures. Anesth. Analg. 98: 11-19 [Abstract] [Full Text]  
• Rose, R. A., Lomax, A. E., Giles, W. R. (2003). Inhibition of L-type Ca2+ current by C-type natriuretic peptide in bullfrog atrial myocytes: an NPR-C-mediated effect. Am. J. Physiol. Heart Circ. Physiol. 285: H2454-H2462 [Abstract] [Full Text]  
• Wright, S. P., Doughty, R. N., Pearl, A., Gamble, G. D., Whalley, G. A., Walsh, H. J., Gordon, G., Bagg, W., Oxenham, H., Yandle, T., Richards, M., Sharpe, N. (2003). Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: A randomized, controlled trial. J Am Coll Cardiol 42: 1793-1800 [Abstract] [Full Text]  
• Palmer, B. R., Pilbrow, A. P., Yandle, T. G., Frampton, C. M., Richards, A. M., Nicholls, M. G., Cameron, V. A. (2003). Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. J Am Coll Cardiol 41: 729-736 [Abstract] [Full Text]  
• Weinberg, E. O., Shimpo, M., Hurwitz, S., Tominaga, S.-i., Rouleau, J.-L., Lee, R. T. (2003). Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker. Circulation 107: 721-726 [Abstract] [Full Text]  
• Nielsen, O. W., McDonagh, T. A., Robb, S. D., Dargie, H. J. (2003). Retrospective analysis of thecost-effectiveness of using plasmabrain natriuretic peptide inscreening for left ventricularsystolic dysfunction in the general population. J Am Coll Cardiol 41: 113-120 [Abstract] [Full Text]  
• McGeoch, G., Lainchbury, J., Town, G.I., Toop, L., Espiner, E., Richards, A.M. (2002). Plasma brain natriuretic peptide after long-term treatment for heart failure in general practice. Eur J Heart Fail 4: 479-483 [Abstract] [Full Text]  
• Anand, I. S., Florea, V. G., Fisher, L. (2002). Surrogate end points in heart failure. J Am Coll Cardiol 39: 1414-1421 [Abstract] [Full Text]  
• Luchner, A., Hengstenberg, C., Lowel, H., Trawinski, J., Baumann, M., Riegger, G. A.J., Schunkert, H., Holmer, S. (2002). N-Terminal Pro-Brain Natriuretic Peptide After Myocardial Infarction: A Marker Of Cardio-Renal Function. Hypertension 39: 99-104 [Abstract] [Full Text]  
• Crilley, J G, Farrer, M (2001). Left ventricular remodelling and brain natriuretic peptide after first myocardial infarction. Heart 86: 638-642 [Abstract] [Full Text]  
• de Lemos, J. A., Morrow, D. A., Bentley, J. H., Omland, T., Sabatine, M. S., McCabe, C. H., Hall, C., Cannon, C. P., Braunwald, E. (2001). The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary Syndromes. NEJM 345: 1014-1021 [Abstract] [Full Text]  
• Tjeerdsma, G., Szabo, B. M., van Wijk, L. M., Brouwer, J., Tio, R. A., Crijns, H. J.G.M., van Veldhuisen, D. J. (2001). Autonomic dysfunction in patients with mild heart failure and coronary artery disease and the effects of add-on {beta}-blockade. Eur J Heart Fail 3: 33-39 [Abstract] [Full Text]  
• Clerico, A., Del Ry, S., Giannessi, D. (2000). Measurement of Cardiac Natriuretic Hormones (Atrial Natriuretic Peptide, Brain Natriuretic Peptide, and Related Peptides) in Clinical Practice: The Need for a New Generation of Immunoassay Methods. Clin. Chem. 46: 1529-1534 [Abstract] [Full Text]  
• Talwar, S, Squire, I.B, Downie, P.F, Mccullough, A.M, Campton, M.C, Davies, J.E, Barnett, D.B, Ng, L.L (2000). Profile of plasma N-terminal proBNP following acute myocardial infarction. Correlation with left ventricular systolic dysfunction. Eur Heart J 21: 1514-1521 [Abstract]  
• COWIE, M. R (2000). BNP: soon to become a routine measure in the care of patients with heart failure?. Heart 83: 617-618 [Full Text]  
• He, Q., LaPointe, M. C. (2000). Interleukin-1{beta} Regulates the Human Brain Natriuretic Peptide Promoter via Ca2+-Dependent Protein Kinase Pathways. Hypertension 35: 292-296 [Abstract] [Full Text]  
• KHAN, K (1999). Is BNP ready for use in clinical practice?. Heart 82: 254-255 [Full Text]